Kapoor Rinky, Shome Debraj, Vadera Sapna, Kumar Vaibhav, Ram Male Shiva
Department of Dermatology, Cosmetic Dermatology and Dermato-Surgery, The Esthetic Clinics, Mumbai, India.
Department of Facial Plastic Surgery & Facial Cosmetic Surgery, The Esthetic Clinics, Mumbai, India.
Plast Reconstr Surg Glob Open. 2020 Aug 25;8(8):e2843. doi: 10.1097/GOX.0000000000002843. eCollection 2020 Aug.
Current treatment modalities are limited in their approach and success for hair loss. QR 678 & QR 678 Neo are new formulations, consisting of a combination of growth factors and peptides. This study demonstrates safety analysis of QR 678 & QR 678 Neo formulation, using in vitro cytotoxicity assay and in vivo animal efficacy.
Factors including vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor-1, keratinocyte growth factor, and copper tripeptide 1 (QR 678) or their biomimetic peptides (QR678 Neo) were suspended in a sterile injectable vehicle. The 3-2,5-diphenyl tetrazolium bromide assay was used to explore the cytotoxic effects of each factor used in the compositions in human keratinocyte cell and human fibroblast cell assays. An in vivo analysis, wherein study animals were given intradermal QR 678 & QR 678 Neo injections, was conducted to assess whether the formulations produce hair growth. Also, hair follicle viability was checked by intradermal injection of the pharmaceutical compositions in secondary alopecia.
In both formulations, a positive response was observed with respect to the number of mice exhibiting hair growth at the injection sites. The injections caused retention of hair in a 0.25-cm radius around the injection site. On cytotoxicity study, all the factors were found to be safe in human keratinocyte cell and human fibroblast cell assay. A positive response was demonstrated in animals on treatment with the chemotherapeutic agent.
Intradermal injections of QR 678 & QR 678 Neo hair growth factor formulations are a safe and efficacious option for alopecia. Results seem encouraging enough to warrant a trial in humans with secondary alopecia, post cancer chemotherapy.
目前的脱发治疗方法在其治疗途径和效果方面存在局限性。QR 678和QR 678 Neo是新的配方，由生长因子和肽组合而成。本研究使用体外细胞毒性试验和体内动物疗效试验对QR 678和QR 678 Neo配方进行安全性分析。
将包括血管内皮生长因子、碱性成纤维细胞生长因子、胰岛素样生长因子-1、角质形成细胞生长因子和铜三肽1（QR 678）或其仿生肽（QR678 Neo）的因子悬浮于无菌可注射载体中。采用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐试验，在人角质形成细胞和人成纤维细胞试验中探究组合物中各因子的细胞毒性作用。进行体内分析，给研究动物皮内注射QR 678和QR 678 Neo，以评估这些配方是否能促进头发生长。此外，通过在继发性脱发中皮内注射药物组合物来检查毛囊活力。
在两种配方中，在注射部位出现头发生长的小鼠数量方面均观察到阳性反应。注射导致注射部位周围0.25厘米半径范围内的毛发得以保留。在细胞毒性研究中，发现所有因子在人角质形成细胞和人成纤维细胞试验中都是安全的。在用化疗药物治疗的动物中显示出阳性反应。
皮内注射QR 678和QR 678 Neo毛发生长因子配方对脱发是一种安全有效的选择。结果似乎令人鼓舞，足以进行一项针对癌症化疗后继发性脱发患者的人体试验。
